Kirkwood, J M <br/><br/>
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 2001 
 - 2370-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2001.19.9.2370  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Cancer Vaccines--immunology<br/>Disease-Free Survival<br/>Female<br/>G(M2) Ganglioside--immunology<br/>Hemocyanins--immunology<br/>Humans<br/>Immunoglobulin G--blood<br/>Immunoglobulin M--blood<br/>Interferon alpha-2<br/>Interferon-alpha--adverse effects<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neoplasm Staging<br/>Prospective Studies<br/>Recombinant Proteins<br/>Saponins<br/>Vaccination<br/>Vaccines, Conjugate--immunology